CytomX Therapeutics Announces Milestone Achievement in Probody T-Cell Engaging Bispecific (TCB)…
CytomX Therapeutics, Inc. announced that it achieved a clinical candidate milestone under its TCB agreement with Astellas. The clinical candidate is the first Probody TCB molecule to…
Read More...
Read More...
